Company profileMixed portfolio#277 of 1,318 in Pakistan1 DRAP alert

OPHTH-PHARMA (PVT) LTD.

Mixed portfolio · 26 pharmaceutical brands of 65 registrations

Ranked #3 of 50 companies in Anti-Infective, Ophthalmologicals

65 registered products 26 pharmaceutical brands 72 distinct molecules 1 DRAP alert

Part of this company's portfolio (“Eye”) is registered under a broad DRAP category rather than distinct molecules, so the molecule count understates its true range.

Company overview

registered products

pharmaceutical brands

distinct molecules

therapeutic classes

DRAP alerts

OPHTH-PHARMA (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 65 product registrations across 72 distinct molecules. Its portfolio is concentrated in Anti-Infective, Ophthalmologicals and Antiinflammatory Agents And Antiinfectives In Combination. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by OPHTH-PHARMA

38 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Eye Conditions 4

Ophthcsporeye10mlRs 331.39 Ophthhypertoniceye10mlRs 77.42 Ophthlubriceye10mlRs 122.81 OphthvitaeyeointRs 224.55

Hormone Regulators 3

K-Kort40Mg 1MlRs 142.5 Kkort40mg/mlRs 137.75 Kkort1mlRs 71.24

Aminoglycoside Antibacterials 2

Amisul500mgceiling Rs 249.31 Amisul100mgceiling Rs 99.72

Anaesthetic, Local 2

Bucane5mgceiling Rs 350.17 Bucane5mg/mlceiling Rs 350.17

Mydriatics And Cycloplegics 1

OPHTH-ATROPINE3.5GRs 95

Other Ophthalmologicals 1

Ophth-Vit.A5gRs 285

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

ceilings with an approval date

not revised in 2+ years

2026

oldest approval year

202624

Top molecules by brand count

Eye23 brands

Dexamethasone3 brands

Ciprofloxacin3 brands

Ofloxacin2 brands

Tobramycin2 brands

Fluorometholone2 brands

Chloramphenicol2 brands

Diclofenac2 brands

Ear2 brands

Metronidazole2 brands

Therapeutic classes

Conditions treated

Price band (DRAP official ceilings)

Registered products priced by source

DRAP-official19 products · Rs 20.6 – Rs 1,956.84

DVAGO7 products · Rs 95 – Rs 316.38

Servaid5 products · Rs 71.24 – Rs 331.39

Median across source: Rs 191.87

Regulatory record

1 alert in the DRAP feed we track.

Recall Alert: Drug Product; Opth-Carb Sterile Intraocular Solution (Batch#OP154) by M/s Op

2023-03-13

Competitive set

Companies whose registered portfolio overlaps most with this one.

REMINGTON PHARMACEUTICAL INDUSTRIES (PVT) LTD.27 shared molecules

Sante (Private) Limited26 shared molecules

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.24 shared molecules

Barrett Hodgson Pakistan (Private) Ltd.23 shared molecules

INNVOTEK PHARMACEUTICALS20 shared molecules

VEGA PHARMACEUTICALS LTD.20 shared molecules

JAENS PHARMACEUTICAL INDUSTRIES PVT LTD20 shared molecules

The Schazoo Pharmaceutical Laboratories (Pvt.) Ltd.19 shared molecules

Atco Pharma International (Pvt) Ltd19 shared molecules

Medipak (Pvt) Ltd18 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

REMINGTON PHARMACEUTICAL INDUSTRIES (PVT) LTD. holds 57 molecules not in this portfolio

Sante (Private) Limited holds 73 molecules not in this portfolio

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 146 molecules not in this portfolio

Get the full profile for OPHTH-PHARMA

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included